pegaptanib

a 28-base ribonucleic acid aptamer covalently linked to two branched 20-kD polyethylene glycol moieties to block the activity of extracellular VEGF, specifically the 165-amino-acid isoform (VEGF165); for treatment of neovascular age-related macular degeneration

Also Known As:

Networked: 218 relevant articles (39 outcomes, 50 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Adamis, Anthony P: 11 articles (04/2009 - 12/2004)
2.	Patel, Manju: 7 articles (10/2007 - 10/2005)
3.	Cunningham, Emmett T: 6 articles (04/2009 - 12/2004)
4.	Goldbaum, Mauro: 5 articles (12/2010 - 10/2005)
5.	Guyer, David R: 5 articles (04/2009 - 12/2004)
6.	Ho, Allen C: 4 articles (01/2012 - 09/2007)
7.	Brown, Gary C: 4 articles (01/2012 - 01/2007)
8.	Ishibashi, Tatsuro: 3 articles (05/2015 - 09/2013)
9.	Yuzawa, Mitsuko: 3 articles (09/2014 - 04/2013)
10.	Sivaprasad, Sobha: 3 articles (01/2014 - 06/2008)

Related Diseases

1.	Macular Degeneration (Age-Related Maculopathy) 12/30/2004 - "Pegaptanib appears to be an effective therapy for neovascular age-related macular degeneration. " 07/01/2005 - "Pegaptanib was effective and safe without a dose-response relation in neovascular, age-related, macular degeneration." 12/01/2010 - "To assess the efficacy of pegaptanib as maintenance therapy in neovascular age-related macular degeneration (NV-AMD) patients after induction therapy. " 09/01/2007 - "Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration." 09/01/2006 - "Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration."
2.	Choroidal Neovascularization 09/01/2007 - "Six eyes from six patients who developed RPE tears while undergoing treatment with pegaptanib for AMD-related fibrovascular pigment epithelial detachment (PED) and occult choroidal neovascularization (CNV) were identified retrospectively. " 06/01/2007 - "Pegaptanib for myopic choroidal neovascularization in a young patient." 10/01/2006 - "Within six weeks of an intravitreal pegaptanib injection, the choroidal neovascularization (CNV) progressed. " 09/01/2013 - "Of Japanese neovascular AMD patients with choroidal neovascularization who showed improvement in visual acuity (VA) with induction therapy, those who were scheduled for intravitreal injections of pegaptanib as maintenance therapy were recruited. " 07/01/2006 - "To report two cases of retinal pigment epithelium (RPE) tears following intravitreal pegaptanib injections for occult choroidal neovascularization. "
3.	Macular Edema 01/01/2015 - "Pegaptanib has been shown to be effective in treating diabetic macular edema (DME). " 01/01/2013 - "Pegaptanib proved to be efficacious and safe for the treatment of diabetic macular edema throughout the 12-month followup. " 01/01/2014 - "The purpose of this study was to evaluate the safety and tolerability of pegaptanib in patients with diabetic macular edema. " 01/01/2015 - "Intravitreal pegaptanib for the treatment of ischemic diabetic macular edema." 01/01/2015 - "In a randomized, double-masked multicenter trial, intravitreal pegaptanib (0.3, 1.0, or 3.0 mg/eye) was administered in patients with diabetic macular edema every 6 weeks for 12-30 weeks. "
4.	Retinal Vein Occlusion 07/01/2010 - "Pegaptanib for branch retinal vein occlusion." 01/01/2011 - "Intravitreal pegaptanib for refractory macular edema secondary to retinal vein occlusion." 11/01/2007 - "Early, well-controlled studies further suggest that pegaptanib may provide therapeutic benefit for patients with diabetic macular edema, proliferative diabetic retinopathy and retinal vein occlusion. " 01/01/2011 - "Pegaptanib sodium is a safe and efficacy treatment for macular edema secondary to branch retinal vein occlusion." 01/01/2010 - "Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion."
5.	Corneal Neovascularization 06/01/2014 - "The mouse model of suture-induced corneal neovascularization was used to assess the antihem- and antilymphangiogenic effect of topically applied pegaptanib. " 01/01/2013 - "Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model." 02/01/2008 - "Pretreatment with pegaptanib sodium appeared to decrease the efficacy of PDT-induced vessel regression in corneal neovascularization, and as such the enhanced efficacy over monotherapy when the agents were delivered simultaneously was not observed. " 01/01/2007 - "We herein hypothesize that topical application of new anti-VEGF agents such as pegaptanib, ranibizumab and bevacizumab are potentially useful for inhibiting corneal neovascularization and restoration of corneal clarity. " 01/01/2013 - "To compare the efficacies of subconjunctival bevacizumab, ranibizumab, and pegaptanib sodium injections for the inhibition of corneal neovascularization in an experimental rat model. "

Related Drugs and Biologics

1.	Sodium
2.	pegaptanib
3.	ranibizumab (Lucentis)
4.	bevacizumab
5.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
6.	Retinaldehyde (Retinal)
7.	1-phenyl-3,3-dimethyltriazene (PDT)
8.	verteporfin (Visudyne)
9.	salicylhydroxamic acid (SHAM)
10.	ROP

Related Therapies and Procedures

1.	Intravitreal Injections
2.	Injections
3.	Light Coagulation
4.	Lasers (Laser)
5.	Photochemotherapy (Photodynamic Therapy)